HPV & Hepatitis Vaccines
- HPV infection
- Local infection at the mucosa
- Attenuation of immune mechanism
- Many viral subtypes
- Viral entry occurs rapidly, but infected cell shows no inflammation
- Virus elimination via natural cell clearance
- Innate immune response, late induction of adaptive response (low antibody levels after long exposure to infection)
- Natural immunity does not reliably prevent from infection
- HBV infection
- Systemic infection
- Viral progression 1 to 6 months from infection to disease
- Strong immune response
- Neutralising antibodies and CTL activation
- Immune mechanisms in subjects who recovered from HBV infection provide lifelong immunity
Related Conference of HPV & Hepatitis Vaccines
March 24-25, 2026
9th International Conference on Vaccines, Immunology and Clinical Trials
Paris, France
HPV & Hepatitis Vaccines Conference Speakers
Recommended Sessions
- Adenovirus vaccine
- Adult Immunization
- Animal vaccination
- Antibodies : Engineering and Therapeutics
- Bacterial Diseases & Viral Vaccines
- Breast cancer vaccine
- Cancer Vaccines & Immunotherapy
- Chicken pox Vaccines
- Child vaccination & Immunization
- Children Vaccines
- Component Vaccines
- DNA & Synthetic Vaccines
- Ebola Vaccines
- Geriatric Immunization
- HIV Vaccines Research & Development
- HIV/AIDS Vaccines
- HPV & Hepatitis Vaccines
- Human Vaccines against Infectious Diseases
- Human Vaccines-Infectious & Non-infectious diseases
- Influenza and Respiratory Vaccine
- Malaria & TB Vaccines
- MMR Vaccines
- Modern Technologies in Vaccine Discovery & Development
- Polio Vaccines
- Preclinical Vaccine Studies
- Recombinant Vaccines
- Recombinant Vector Vaccines
- Stem Cell Immunology
- Tdap Vaccines
- Translational, Clinical Evaluation & Field Trials of Vaccines
- Travel Immunization
- Tuberculosis Vaccines
- Vaccine Adjuvants & Delivery Technologies
- Vaccines & Immunization
- Vaccines Dermatology
- Vaccines Epidemiology
- Vaccines for Immune mediated Diseases
- Vaccines for pregnant women
- Vaccines Industry & Manufacturing
- Vaccines Preclinical & Clinical Trials
- Veterinary Vaccines
Related Journals
Are you interested in
- Adjuvants and Immunopotentiators - VACCINE CONGRESS 2025 (Japan)
- Adult and Elderly Vaccination Strategies - VACCINE CONGRESS 2025 (Japan)
- Advancements in Vaccine Research and Development - Vaccines R&D 2026 (France)
- Advances in Pediatric Vaccines - Vaccines R&D 2026 (France)
- Adverse reactions to the vaccination - Vaccines Congress-2025 (Canada)
- AI and Data Science in Vaccine Discovery - VACCINE CONGRESS 2025 (Japan)
- Antimicrobial Resistance (AMR) - VACCINES WORLD 2025 (Germany)
- Antimicrobial Resistance and Vaccines - VACCINE CONGRESS 2025 (Japan)
- Antinatal vaccinations - Vaccines Congress-2025 (Canada)
- Bioprocessing and Manufacturing - VACCINES WORLD 2025 (Germany)
- Booster Doses and Heterologous Vaccine Regimens - VACCINE CONGRESS 2025 (Japan)
- Cancer Vaccines and Immunotherapy - VACCINES WORLD 2025 (Germany)
- Cancer Vaccines and Immunotherapy - VACCINE CONGRESS 2025 (Japan)
- Clinical Trials - VACCINES WORLD 2025 (Germany)
- Clinical Trials Design and Methodologies - Vaccines R&D 2026 (France)
- Conjugate Vaccine - VACCINES WORLD 2025 (Germany)
- Conjugated and combination vaccinations - Vaccines Congress-2025 (Canada)
- Coronavirus (COVID-19) & Pandemic Vaccines - VACCINES WORLD 2025 (Germany)
- Corporate Innovation, Sponsorship & Exhibition - VACCINE CONGRESS 2025 (Japan)
- COVID-19 Vaccine Impact and Learnings - VACCINE CONGRESS 2025 (Japan)
- Creation and development of vaccines - Vaccines Congress-2025 (Canada)
- DNA, RNA & SYNTHETIC VACCINES - Vaccines Congress-2025 (Canada)
- DNA-RNA Vaccines - VACCINES WORLD 2025 (Germany)
- Emerging and Re-Emerging Diseases - VACCINES WORLD 2025 (Germany)
- Emerging Infectious Diseases and Vaccine Development - Vaccines R&D 2026 (France)
- Ethical Considerations in Vaccine Development and Distribution - Vaccines R&D 2026 (France)
- Fungal/Bacterial/Viral/Parasitic/STD Vaccines - VACCINES WORLD 2025 (Germany)
- Global Immunization Programs and Policy - VACCINE CONGRESS 2025 (Japan)
- Global Immunization Strategies and Policy - Vaccines R&D 2026 (France)
- HIV , Malaria & TB vaccines - Vaccines Congress-2025 (Canada)
- HIV Vaccines - VACCINES WORLD 2025 (Germany)
- Immune Profiling - VACCINES WORLD 2025 (Germany)
- Immunology of Infectious Diseases - Vaccines R&D 2026 (France)
- Immunotherapy and Personalized Medicine - Vaccines R&D 2026 (France)
- Infectious and Non-Infectious Diseases - VACCINES WORLD 2025 (Germany)
- Infectious Disease Vaccines - VACCINE CONGRESS 2025 (Japan)
- Influenza and Respiratory Vaccines - VACCINES WORLD 2025 (Germany)
- Innovations in Vaccine Cold Chain and Storage - Vaccines R&D 2026 (France)
- Manufacturing, Supply Chain, and Distribution - VACCINE CONGRESS 2025 (Japan)
- Nanotechnology in Vaccine Delivery - VACCINE CONGRESS 2025 (Japan)
- Next-Generation Vaccine Technologies - VACCINE CONGRESS 2025 (Japan)
- Pediatric and Neonatal Vaccines - VACCINE CONGRESS 2025 (Japan)
- rDNA technology in vaccine development - Vaccines Congress-2025 (Canada)
- Recent advances in vaccine development - Vaccines Congress-2025 (Canada)
- Regulatory Approaches in Vaccine Development - Vaccines R&D 2026 (France)
- Role of Adjuvants in Vaccine Efficacy - Vaccines R&D 2026 (France)
- Role of AI and Big Data in Vaccine Research - Vaccines R&D 2026 (France)
- The COVID-19 vaccine's next-generation RNA platforms and mRNA - Vaccines Congress-2025 (Canada)
- Thermo Stabilized Vaccines - VACCINES WORLD 2025 (Germany)
- Toxoid vaccination - Vaccines Congress-2025 (Canada)
- Translational Immunology and Vaccine Development - Vaccines R&D 2026 (France)
- Vaccine Adjuvants - VACCINES WORLD 2025 (Germany)
- Vaccine and Vaccination - Vaccines Congress-2025 (Canada)
- Vaccine Delivery Systems: Innovations and Challenges - Vaccines R&D 2026 (France)
- Vaccine Development for Cancer Immunotherapy - Vaccines R&D 2026 (France)
- Vaccine Development for Vector-Borne Diseases - Vaccines R&D 2026 (France)
- Vaccine efficiency and well-being - Vaccines Congress-2025 (Canada)
- Vaccine Equity and Access in Low-Resource Settings - Vaccines R&D 2026 (France)
- Vaccine for infectious illnesses in humans - Vaccines Congress-2025 (Canada)
- Vaccine Hesitancy and Public Perception - Vaccines R&D 2026 (France)
- Vaccine Manufacturing and Distribution - Vaccines R&D 2026 (France)
- Vaccine manufacturing technologies - Vaccines Congress-2025 (Canada)
- Vaccine Production, Supply & Logistics - VACCINES WORLD 2025 (Germany)
- Vaccine Research and Clinical trials - Vaccines Congress-2025 (Canada)
- Vaccine Research and Development - VACCINES WORLD 2025 (Germany)
- Vaccine Research Ethics and Regulations - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety and Pharmacovigilance - Vaccines R&D 2026 (France)
- Vaccine Safety and Pharmacovigilance - VACCINE CONGRESS 2025 (Japan)
- Vaccine Safety, Efficacy & Regulatory Affairs - VACCINES WORLD 2025 (Germany)
- Vaccines against non-traditional illnesses - Vaccines Congress-2025 (Canada)
- VACCINES FOR CANCER - Vaccines Congress-2025 (Canada)
- Veterinary and Zoonotic Vaccines - VACCINE CONGRESS 2025 (Japan)
- Veterinary Vaccine - VACCINES WORLD 2025 (Germany)
- Workshops and Poster Sessions - VACCINE CONGRESS 2025 (Japan)
- Zika Virus vaccines - Vaccines Congress-2025 (Canada)